Plain-English translation of NCT07363694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called PF-07275315 can help people with moderate-to-severe COPD (a lung disease that makes breathing difficult). Participants will receive either the new medication or a placebo (a dummy injection with no medicine) as injections over the course of several months to see if the treatment is safe and actually helps reduce breathing problems and disease flare-ups.
COPD is a serious condition that makes it hard to breathe and significantly affects quality of life, especially when people experience sudden flare-ups. Researchers are testing this medication to see if it can reduce how often these flare-ups happen and help people breathe better than current treatments alone.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive multiple injections of either the new medication or a placebo at the study clinic over 6 months (Phase 2) or 1 year (Phase 3). You'll come back for 11 to 18 clinic visits over the course of your participation, where doctors will check how you're doing, measure your breathing, and watch for any side effects. The study will compare your results with those of people who received the placebo to see if the medication truly helps.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States